GLP-3 is strictly for laboratory research and is commonly employed in the following investigational areas:

Multi-Receptor Synergism & Metabolic Flux

GLP-3 is utilized as a chemical probe to study the biophysics of simultaneous GLP-1, GIP, and glucagon receptor activation. Researchers employ this peptide to quantify the synergistic dose-dependent stimulation of intracellular cyclic AMP (cAMP) and the subsequent regulatory effects on glucose-dependent signaling and lipid metabolism.

Hepatic and Adipocyte Bioenergetics

Experimental models involving differentiated adipocytes and hepatocytes utilize this compound to study its dual role in incretin-mediated insulinotropic effects and glucagon-driven lipolysis. Researchers quantify changes in lipid droplet mobilization, hepatic fat oxidation, and energy expenditure rates to understand the broader role of tri-agonism in metabolic homeostasis.

Pancreatic Beta-Cell and Alpha-Cell Crosstalk

In vitro studies employ triple agonists to observe their impact on cellular architecture within pancreatic models. Investigations focus on how GIP and GLP-1 signaling protects beta-cells and stimulates insulin synthesis, while evaluating the opposing/modulatory effects of glucagon receptor engagement on alpha/beta-cell crosstalk.

Pathway / Mechanistic Context

The primary mechanism of action for GLP-3 in research settings involves the targeted, unimolecular activation of three distinct GPCRs.

• GLP-1R Activation: Stimulates adenylate cyclase, leading to cAMP accumulation, which promotes glucose-dependent insulin transcription and exocytosis in beta-cell models.
• GIPR Activation: Acts synergistically with GLP-1 to enhance the insulinotropic response and modulates lipid storage pathways in adipocyte assays.
• GCGR (Glucagon Receptor) Activation: Initiates catabolic signaling cascades that stimulate glycogenolysis and hepatic fat oxidation, ultimately increasing resting cellular energy expenditure.

Preclinical Research Summary

Published preclinical literature documents investigations of unimolecular triple agonists across multiple experimental models for pathway characterization:

• Metabolic Assays: Studies in obese murine models have observed that GLP-1/GIP/glucagon tri-agonists achieve significant reductions in body weight, driven heavily by GCGR-mediated increases in energy expenditure alongside GIPR- and GLP-1R-driven calorie intake reduction.
• Hepatic Lipid Depletion: Research indicates that the administration of stable tri-agonists reduces liver triglycerides and plasma alanine aminotransferase in metabolic models, suggesting improvements in liver health.
• Cellular Bioenergetics: Data from metabolic assays suggest that the inclusion of glucagon agonism alongside GLP-1 and GIP enhances total fat oxidation and alters substrate utilization without overriding the glucose-lowering benefits of the incretins.

Form & Analytical Testing

This material is produced via robust chemical synthesis and supplied as a lyophilized (freeze-dried) powder.

• Lyophilization: Removes water content under vacuum to maintain compound integrity and extend shelf-life.
• Identity Verification: Each lot undergoes Mass Spectrometry (MS) to confirm molecular weight and identity.
• Purity Verification: High-Performance Liquid Chromatography (HPLC) is performed to ensure the product meets the ≥99% purity standard required for reproducible research data.

Referenced Citations

References are provided for informational purposes only and are not clinical claims.

• Coskun, T., Urva, S., Roell, W. C., et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism, 34(9), 1234-1247.e9. https://doi.org/10.1016/j.cmet.2022.07.013
• Doub, J., et al. (2025). Next generation dual GLP-1/GIP, GLP-1/glucagon, and triple GLP-1/GIP/glucagon agonists: a literature review. Nutrition, Metabolism and Cardiovascular Diseases, 35(12), 104213.https://www.sciencedirect.com/science/article/abs/pii/S0939475325003679
• Brzdęk, K., & Brzdęk, M. (2024). Triple agonists of GIP, GLP-1, and glucagon – the future of obesity treatment. Medical Science Pulse, 18(4), 48-58. https://doi.org/10.5604/01.3001.0054.8367
• Fosam, A., et al. (2024). The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor – An Update. Endocrinology and Metabolism.https://pubmed.ncbi.nlm.nih.gov/38356208/
• ACS Publications. (2025). Strategic Design of Triple GLP-1R/GCGR/GIPR Agonists with Varied Receptor Potency. Journal of Medicinal Chemistry.https://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.5c02032

• Stable at room temperature for up to 90 days. For long-term storage, keep at -20°C (-4°F) or colder.
• Once mixed with a solvent (e.g., bacteriostatic water), the solution must be stored at 4 °C (39°F) and utilized within 30 days. Avoid repeated freeze-thaw cycles, as this degrades the peptide structure.

RESEARCH USE ONLY

This product is intended strictly for laboratory research use only. It is not for human or veterinary use. It is not intended for diagnosis, treatment, cure, or prevention of any disease. All purchases are subject to our Terms of Service and Purity Guarantee.

No COAs available for this product.